Gottlieb At FDA: Industry Will Look For User-Fee Deal Support, Restrained Regulations

After months of waiting on whether President Trump would pick a conventional FDA commissioner candidate or go off the beaten path, the White House appears to be taking the former approach. Trump is expected to nominate Scott Gottlieb, a George W. Bush administration FDA alum, physician and long-time conservative voice on health policy. Gottlieb will favor reduced regulatory burdens, and industry hopes he will help push forward a device user-fee reauthorization agreement.

FDASignBldg21Entrance_1200x675

President Trump is expected to tap former FDA and CMS official Scott Gottlieb to run FDA, an agency that the president recently criticized for impeding innovative new medical products. Gottlieb is likely to favor reducing regulatory burdens for companies. But industry hopes one of his first priorities will be to help push a user-fee reauthorization agreement that was negotiated with the Obama administration through Congress.

The choice comes after months of uncertainty and signs that the president was flirting with making a pick for the commissioner post that would more sharply upend the regulatory system...

More from Regulation

More from Policy & Regulation